Pharmacology of dl-5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy) coumarin hydrochloride (CS-359), a new beta-adrenergic blocking agent.
D031841:Aconitum; D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D000818:Animals; D000889:Anti-Arrhythmia Agents; D001001:Anura; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004558:Electric Stimulation; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D007928:Lethal Dose 50; D051379:Mice; D010042:Ouabain; D011412:Propanolamines; D011433:Propranolol / Q000494:pharmacology; D012160:Retina / Q000187:drug effects; D012584:Sciatic Nerve / Q000187:drug effects; D013233:Stellate Ganglion / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D000889:Anti-Arrhythmia Agents; D011412:Propanolamines; D010042:Ouabain; D011433:Propranolol; D007545:Isoproterenol; C024221:bucumolol